Want to see SE:BIOSGN full AI Analyst Report?
BIOSGN Stock Chart & Stats
kr42.60
<kr0.01(1.20%)
At close: 4:00 PM EST
kr42.60
<kr0.01(1.20%)
Day’s Range― - ―
52-Week Rangekr4.28 - kr58.00
Previous CloseN/A
Volume13.64K
Average Volume (3M)126.26K
Market Cap
kr11.74M
Enterprise Value-kr15.54M
Total Cash (Recent Filing)kr15.37M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-1.09
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.20
Shares Outstanding2,348,232
10 Day Avg. Volume207,862
30 Day Avg. Volume126,261
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)7.89
Price to Sales (P/S)0.00
P/FCF Ratio-2.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-10
Revenue Forecast (FY)kr1.40M
Bulls Say, Bears Say
Bulls Say
Low Leverage / No DebtNo reported debt is a durable structural strength for an R&D-stage biotech: it reduces fixed cash obligations and interest risk, preserves flexibility to time fundraising or partnerships, and lowers near-term solvency pressure while development programs proceed.
Clear Lead Asset (BSG005)Having a defined lead asset (BSG005) focused on invasive fungal infections gives the company a concentrated development pathway. This focus helps allocate R&D resources efficiently and supports targeted clinical and regulatory planning over the coming months.
Evidence Of Controllable Cash BurnManagement has shown the ability to moderate spending year-to-year, indicating some control over R&D and operating expenses. That operational flexibility can meaningfully extend runway or reduce dilution risk if prioritized during funding cycles.
Bears Say
No Commercial Revenue (pre-commercial)Zero revenue since 2022 means the company remains entirely pre-commercial and reliant on external financing to fund operations. Over the next 2-6 months this structural reliance increases execution and financing risk, as there are no sales or royalties to offset burn.
Sharply Rising Cash Burn In 2025The large increase in cash burn in 2025 materially raises near-term funding needs and the likelihood of capital raises. This structural trend shortens runway and increases dilution or partnership pressure, limiting strategic options absent new capital.
Erosion Of Equity And AssetsThe steep decline in equity and total assets signals a shrinking resource cushion to absorb further losses. This structural depletion heightens solvency and financing risk, reducing flexibility to sustain trials or pivot programs without fresh capital.
Biosergen AB News
BIOSGN FAQ
What was Biosergen AB’s price range in the past 12 months?
Biosergen AB lowest stock price was kr4.28 and its highest was kr58.00 in the past 12 months.
What is Biosergen AB’s market cap?
Biosergen AB’s market cap is kr11.74M.
When is Biosergen AB’s upcoming earnings report date?
Biosergen AB’s upcoming earnings report date is Aug 19, 2026 which is in 45 days.
How were Biosergen AB’s earnings last quarter?
Currently, no data Available
Is Biosergen AB overvalued?
According to Wall Street analysts Biosergen AB’s price is currently Overvalued.
Does Biosergen AB pay dividends?
Biosergen AB does not currently pay dividends.
What is Biosergen AB’s EPS estimate?
Biosergen AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biosergen AB have?
Biosergen AB has 2,348,232 shares outstanding.
What happened to Biosergen AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biosergen AB?
Currently, no hedge funds are holding shares in SE:BIOSGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biosergen AB
Biosergen AB is a biopharmaceutical company specializing in the creation of antifungal medications. Its key development initiative is BSG005, an experimental antifungal drug candidate engineered to treat critical invasive fungal infections. The firm was established in 2004 and operates from its headquarters located in Solna, Sweden.